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Abstract
Understanding the binding mode of agonists to adrenergic receptors is crucial to enabling improved rational design of new
therapeutic agents. However, so far the high conformational flexibility of G protein-coupled receptors has been an obstacle
to obtaining structural information on agonist binding at atomic resolution. In this study, we report microsecond classical
molecular dynamics simulations of b1 and b2 adrenergic receptors bound to the full agonist isoprenaline and in their
unliganded form. These simulations show a novel agonist binding mode that differs from the one found for antagonists in
the crystal structures and from the docking poses reported by in silico docking studies performed on rigid receptors.
Internal water molecules contribute to the stabilization of novel interactions between ligand and receptor, both at the
interface of helices V and VI with the catechol group of isoprenaline as well as at the interface of helices III and VII with the
ethanolamine moiety of the ligand. Despite the fact that the characteristic N-C-C-OH motif is identical in the co-crystallized
ligands and in the full agonist isoprenaline, the interaction network between this group and the anchor site formed by
Asp(3.32) and Asn(7.39) is substantially different between agonists and inverse agonists/antagonists due to two water
molecules that enter the cavity and contribute to the stabilization of a novel network of interactions. These new binding
poses, together with observed conformational changes in the extracellular loops, suggest possible determinants of receptor
specificity.
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Introduction
Beta adrenergic receptors are a class of transmembrane
receptors responsible for binding catecholamines, such as the
endogenous hormone adrenaline or the neurotransmitter nor-
adrenaline. They belong to the G-protein-coupled receptors
(GPCRs) family and are crucially involved in heart muscle
contraction (b1), smooth muscle relaxation (b2) and lipolysis
enhancement (b3). As a consequence, their signaling pathways are
central for cardiac function regulation and relaxation of vascular
and bronchial tone. The development of a large number of
compounds able to modulate the activity of such receptors has
been a major goal for the pharmaceutical industry to improve the
clinical treatment of various diseases including hypertension, heart
failure, asthma and preterm labor [1].
Since distinction between b adrenergic receptors can be based
upon their relative affinities for the endogenous catecholamine
agonists adrenaline and noradrenaline, determination of the
differences that are responsible for their characteristic role upon
agonist activation is crucial for the development of selective b-
blockers [2].
The pharmacological characteristics of adrenergic receptors
and their relative affinities and efficacies have been studied
exhaustively, leading to the identification of a large number
of clinically relevant agonists and antagonists. However, only
recently determination of the crystal structures of b2 and b1
adrenergic receptors bound to inverse agonists/antagonists has
provided a view of the binding mode of ligands inside the
orthosteric binding pocket with atomic resolution [3,4]. In
particular, these crystal structures have confirmed that the
crystallized ligands are engaged in specific interactions with a
set of amino acid side chains in helices III, V, VI and VII that
extensive mutation analyses already suggested as preferred
interaction partners for catecholamines [5,6,7,8,9,10]. In addi-
tion, the X-ray data suggested a functional role for the second
extracellular loop (ECL2), based on its structure and close
proximity with the bound ligand.
An atomistic description of the binding mode of agonists, on
the other hand, is still lacking, and structure determination
of adrenergic receptors in complex with agonists has so far
been proven elusive. To address this pharmacologically crucial
issue, structure-based drug design using the antagonist-bound
b2AR structure as a template have been recently reported
[11,12,13,14,15,16]. These studies have primarily focused on the
ability to identify partial/full agonists with docking based in silico
screening methods, focusing on the molecular description of the
strong agonist-specific [6,10] polar interaction network between
the catechol functional group and an anchor site formed by three
serines in helix V, and the possible displacement of this helix to
ease agonist binding [13,16].
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binding is an intrinsically dynamical event that occurs via
kinetically distinguishable conformational intermediates [20],
and indeed recent in silico screening of approximately 1 million
of commercially available ‘‘lead-like’’ molecules has confirmed an
apparent bias toward inverse agonists among the docking hits
[14].
On the other hand, it is known that agonist efficacy can be
modulated by a number of allosteric factors, including G protein
binding [21], GDP and GTP concentration [21], pH [22] and
oligomerization state [23]. In particular, recent NMR studies on
rhodopsin [24] and on b2AR [25] have revealed that the
conformation of the extracellular surface of these receptors
changes upon activation and that, in b2AR, drugs exhibiting
different efficacies towards G-protein activation can stabilize
distinct conformations of the extracellular loops, thus demonstrat-
ing a conformational coupling between this region and the
orthosteric binding site. These findings are of special interest in
view of the fact that the binding sites are very similar amongst b
adrenergic receptors, whereas the extracellular loops are remark-
ably diverse and are therefore a possible target for the discovery of
subtype-selective drugs.
To further elucidate agonist binding in the family of b
adrenergic receptors, taking into account inherent receptor
flexibility and explicit solvation known to be crucial for GPCR
function [26,27,28,29], we have carried out submicrosecond MD
simulations of b1 and b2 adrenergic receptors bound to the potent
agonist isoprenaline as well as in their apoforms. In order to
properly analyze the agonist-induced local conformational chang-
es in the two receptors, we also compare these simulations with
previously reported MD simulations of b1 and b2 adrenergic
receptors bound to the antagonist cyanopindol and the to the
inverse agonist carazolol [30].
Anticipating our results, our simulations suggest that internal
water molecules, that are usually left out in rigid docking experi-
ments, play a major role in stabilizing agonist-receptor interac-
tions, participating in two complex hydrogen bond networks
between the agonist and the receptor. One of them involves the
catechol moiety of the agonist while the other its ethanolamine
part, and both differ from the inverse agonist interactions reported
in the recently solved crystal structures of b adrenergic receptors
[3,4]. In addition, the specific behavior of the extracellular loops
helps rationalize the allosteric activity of this region and provides
meaningful insights into drug-receptor specificity.
Methods
All simulations are based on the crystal structure of human b2
Adrenergic Receptor (Protein Data Bank code: 2RH1) [3], and on
chain B of the crystal structure of partially mutated (b1AR-m23)
turkey b1 Adrenergic Receptor (Protein Data Bank code: 2VT4)
[4]. Missing amino acids (including the third extracellular loop and
the C and N termini) and ionizable side chains have been modeled
according to Ref. [30]. In b1AR, residues S68, V90, A227, L282,
A327, M338 are mutated back to R68, M90, Y227, A282, F327
and F338.
The explicit membrane environment is formed by 1-stearoyl-
2-oleoyl-sn-glycero-3-phosphoethanolamine (SOPE) lipids, and
the systems are immersed in a box of SPC water [31]. Sodium
and chloride ions were added to the aqueous phase to obtain an
overall neutral system at physiological ion concentration. The
systems consist of approximately 100.000 atoms in a box of size
100 cubic A ˚.
The all-atom AMBER/parm99SB [32] force field was used and
all bound ligands (S-carazolol, S-cyanopindolol and R-isoprena-
line) carry a net positive charge of +1e (see Figure 1). The atomic
charges for these ligands were derived by RESP [32,33,34] fitting
using HF/6-31G* optimized structures and electrostatic potentials
obtained using the Gaussian03 package [35]. The forcefield para-
meters for the ligands are reported in Supplementary Information
(Dataset S1, S2 and S3).
All data collections and equilibration runs were done using
GROMACS 4 [36]. Electrostatic interactions were calculated with
the Ewald particle mesh method [37], with a real space cutoff of
12 A ˚. Bonds involving hydrogen atoms were constrained using the
LINCS [38] algorithm and the time integration step was set to
2 fs. The systems were coupled to a Nose ´-Hoover thermostat
[39,40] and to an isotropic Parrinello-Rahman barostat [41] at a
temperature of 310K and a pressure of 1 atm.
Simulations of the apoforms and isoprenaline-bound b2AR and
b1AR were started from the equilibrated carazolol-bound and
cyanopindolol-bound structures taken from Ref. [30] after
removal of the bound ligand or replacement of the bound
carazolol with isoprenaline using a superposition of the N-C-C-
OH motif shared by many adrenergic receptor agonists and
antagonists. The systems were then slowly heated up to 310 K in
1040 ps without restraints.
Data analysis was performed on the following systems (between
parenthesis the length of the corresponding MD runs in the case
of a deprotonated Asp(2.50) and of a protonated Asp(2.50)) for a
cumulated length of 6.5 ms: carazolol-bound b2AR (820 ns;
600 ns), isoprenaline-bound b2AR (830 ns; 500 ns), unliganded
b2AR (800 ns; 450 ns); cyanopindolol-bound b1AR (820 ns;
600 ns), isoprenaline-bound b1AR (500 ns; 500 ns), unliganded
b1AR (500 ns). Unless stated otherwise, the analyses des-
cribed in the text refer to the simulations with deprotonated
Asp(2.50).
All data analysis were done using GROMACS [36] utilities and
all molecular images were made with Visual Molecular Dynamics
(VMD) [42]. Hydrogen bonds are defined by a heavy atom
distance cutoff of 3 A ˚ and an angle cutoff of 20 degrees.
Author Summary
G-protein coupled receptors are the largest family of
membrane proteins in the human genome and they
constitute the largest class of drug targets. Amongst them,
beta adrenergic receptors are involved in the regulation of
muscular and vascular tone and are thus molecular targets
for the treatment of various diseases including hyperten-
sion, heart failure and asthma. The function of these
receptors is regulated via the binding of endogenous or
exogenous ligands that can either lead to activation
(agonists) or inactivation (inverse agonists/antagonists).
However, structure determination of these receptors has
been very elusive, and the few atomic resolution structures
that are available so far have only been obtained in the
presence of inverse agonists or antagonists. In order to
study the binding mode of agonists inside the binding
pocket, we employ all-atom molecular dynamics. This
facilitates the study of the details of the interaction
between agonist and receptor in full atomistic detail. We
find that agonists binding to beta adrenergic receptors
require the formation of a highly structured hydrogen
bond network that is further stabilized by the presence of
internal water molecules. The observed local rearrange-
ments also help provide insights into the molecular origin
of the differences between agonist and inverse agonist
binding.
Agonist Binding to b Adrenergic Receptors
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Orthosteric binding site
Comparison of the chemical similarities of b adrenergic
receptor ligands suggests that while some interactions might be
common for agonists and antagonists, others can be expected to be
specific for agonists only. In particular, while most b adrenergic
agonists and antagonists (including the co-crystallized cyanopin-
dolol and carazolol) present a positively charged amine or
ethanolamine groups, the presence of the polar catechol group is
strongly agonist specific.
At the same time, it is known that while antagonist binding to b
adrenergic receptors is largely entropy driven, with only a small
enthalpy component, the binding of agonists is associated with a
large decrease in enthalpy [43]. These considerations suggest
formation of a large structured hydrogen bond network, probably
located in close proximity to Ser(5.42) [10], Ser(5.43) [6] and
Ser(5.47) [6] in helix V, as possible key component of agonist
binding.
The crystal structures of the antagonist/inverse agonist bound
forms have indeed confirmed these considerations, showing that
the carbazole heterocycle of carazolol and the indole moiety of
cyanopindolol interact with the receptor mainly via hydrophobic
interactions and a lone hydrogen bond with Ser(5.42), while
Asp(3.32) and Asn(7.39) form a complementary H-bond network
with the ethanolamine group of the ligands.
To understand the binding mode of agonists inside the binding
pocket of adrenergic receptors as well as the conformational
changes induced in the receptor by the presence of different ligand
effectors, we performed MD simulations ranging between 500 ns–
830 ns of b1 and b2 adrenergic receptors in their apoforms, and
bound to the full agonist isoprenaline. The simulations were
started from receptor structures bound to the co-crystallized
antagonist cyanopindolol and the inverse agonist carazolol
previously equilibrated in an explicit membrane environment
(see Methods and ref. [44]).
Root mean square deviation (RMSD) analysis of the backbone
atoms of all alpha helices as well as of the ligand binding site,
defined as all residues within 5 A ˚ from the bound ligand in the
crystal structures, suggests that the simulations are equilibrated
within approximately one hundred nanoseconds (see Figure 2).
Very little global structural rearrangements with respect to the
crystal structures, in line with previously reported MD simulations
of the same systems in their apo [45] and antagonists-bound [44]
forms, are observed.
At the same time, the apoforms of the receptors need a longer
equilibration time, especially in the case of b1AR, where
equilibration is reached only after approximately 200 ns. This
difference is related to the extent of internal solvation-induced
rearrangements that take place in the apoform, in contrast to the
case of the ligand bound receptors where a set of hydrophobic
residues contributes to ligand stabilization inside the binding
pocket with only few internal water molecules playing a crucial
role.
Interestingly, the ligand binding site remains very close to the
original conformation both in MD simulations of the isoprenaline-
bound forms and in the unliganded systems, suggesting that only
local rearrangements take place. The most significant of these local
changes are due to conformational transitions of crucial residue
Phe193 in the second extracellular loop (ECL2) which cause the
fluctuations of the active site RMSD in the isoprenaline-bound
b2AR simulations (green line in the right panel of Figure 2) and
their functional significance will be discussed in more detail below.
Agonist interactions with helices V–VI. After equilibra-
tion, the catechol moiety of isoprenaline is engaged in a stable
hydrogen bond network (see Figure 3 and Table S1 of Supple-
mentary Information) formed by the two hydroxyl groups of the
ligand with the side chains of Ser(5.42) [10], Ser(5.43) [6] and
Ser(5.47) [6], as well as Asn(6.55) [8].
In particular, the Ser(5.42) side chain oxygen directly hydrogen
bonds one of the two hydroxyl groups of isoprenaline, while
Ser(5.47) can either form a direct H-bond with one hydroxyl group
of the ligand (in b2AR) or a water mediated hydrogen bond network
withthe catechol moiety(b1AR). On the other hand,Ser(5.43) is not
directly interacting with the bound ligand but instead stabilizes the
side chainconformationofAsn(6.55)via anhydrogen bondbetween
its side chain oxygen and one of the two hydrogen atoms of the NH2
moiety of Asn(6.55), restraining the conformation of the other
hydrogen atom of Asn(6.55) side chain to form an additional H-
bond with a catechol oxygen of isoprenaline. This conformation of
Asn(6.55) is further stabilized in b2AR by an additional hydrogen
bond between its side chain oxygen and the hydroxyl group of
Tyr(7.35) that is mutated into a phenylalanine residue in b1AR, the
lone sequence difference between the two receptors in the
orthosteric binding site. Interestingly, despite the different behav-
iour of Asn(6.55) in the two systems (as suggested by the time
Figure 1. Chemical structures of adrenergic ligands. Chemical structures of the co-crystallized inverse agonists S-carazolol (left) and S-
cyanopindolol (center) and of the full agonist R-isoprenaline (right). In the green oval, the C-C-O-H motif discussed in the Results section is
highlighted.
doi:10.1371/journal.pcbi.1001053.g001
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Supplementary Information) the most stable conformation is the
same for both the b1 and the b2.
The two systems differ, however, in the degree of hydration of
the catechol-helix V interaction network: while in b2AR waters are
sequestrated and can interact with the catechol moiety only in the
extracellular side of the binding pocket, in b1AR two water
molecules play a crucial role in modulating the interaction
between the drug and the serine triplet, mainly via Ser(5.47).
These two internal water molecules are present during the entire
simulation time in both systems (b1AR and b2AR) at the interface
between helices III and V but do interact directly with isoprenaline
only in the b1AR simulation.
Interestingly, a recent in silico docking study on b2AR, has
reported that motion of helix V relatively to the binding pocket
could produce a marked enhancement of the calculated binding
affinities for agonist compounds [13]. In the MD simulations of
both systems, however, helix V shows very limited movement,
suggesting that side chain reorientation is sufficient to achieve
stable binding between receptor and agonist. It is likely that the
absence of internal water molecules in the docking protocol could
be responsible for unfavorable interactions (and thus scoring hits)
with helix V in the crystal structure conformation, while, on the
other hand, internal water molecules in the MD simulations play a
significant role in the stabilization of the interaction network
between agonist and receptor.
Figure 2. Transmembrane region and binding pocket root mean square deviation. Root mean square deviation (RMSD) of backbone
atoms of all alpha helices (left) and of residues in the binding site (right) for unliganded b2AR (black), unliganded b1AR (blue), isoprenaline-bound
b2AR (green) and isoprenaline-bound b1AR (red).
doi:10.1371/journal.pcbi.1001053.g002
Figure 3. Agonist interactions with helices V and VI. MD snapshots of the hydrogen-bond interaction network between isoprenaline and
Ser(5.42), Ser(5.43), Ser(5.47), Asn(6.55), Tyr/Phe(7.35) and internal water molecules in b2AR (left) and b1AR (right).
doi:10.1371/journal.pcbi.1001053.g003
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helix VI (described by the Ca-Ca distance between Asp(3.32) and
Asn(6.55)) decreases in both b1AR and b2AR by approximately
1A ˚ with respect to the crystal structures and MD simulations with
inverse agonists. Even though the two residues remain far apart
(the average distance between Asp(3.32) and Asn(6.55) is around
14.660.4 A ˚ in the MD simulations), this movement seems to be in
line with biophysical studies [8,46] suggesting that the distance
between these two residues should decrease during activation.
Interestingly, in the simulations of unliganded b1AR and b2AR
the behavior of the relative distances between helix III and helices
V and VI is remarkably different. While in b2AR both helix V and
helix VI move away from helix III as a consequence of water
entering the binding pocket, in b1AR the distance between helix
III and helix VI slightly increases, while the distance between helix
III and helix V decreases despite hydration of the cavity (Figure
S2, Supplementary Information).
The conformational changes of the binding pocket in the two
receptors are thus similar in the presence of isoprenaline, but
different for the unliganded receptors. Isoprenaline is a potent full
agonist for both b1 and b2 adrenergic receptors, while the two
receptors show a considerably different amount of constitutive
activity. Therefore, the different behavior of the binding pocket in
the simulations could be linked to the specific activity of the two
receptors under the effect of isoprenaline or in the absence of any
external effector molecule.
Agonist interactions with helices II, III and VII. On the
opposite side, most adrenergic ligands (agonists, antagonists and
inverse agonists) present a positively charged amine or ethano-
lamine group. The crystal structures of the co-crystallized inverse
agonists suggest that this group forms a complementary H-bond
network with Asp(3.32) and Asn(7.39) at the interface between
helices II, III and VII, where Asn(7.39) acts both as a H-bond
acceptor and donor to the amine nitrogen and hydroxyl oxygen of
the ligands and Asp(3.32) is a H-bond acceptor for the protonated
amine nitrogen and the hydroxyl group of the ligands (see Figure 4,
panel A). This network remains stable during submicrosecond MD
simulations of carazolol-bound b2AR and of cyanopindolol-bound
b1AR [44].
Despite the fact that the characteristic N-C-C-OH motif is
identical in the co-crystallized ligands and in the full agonist
isoprenaline (see Figure 1), MD simulations show that the
dynamical behavior of the network of interactions of this group
is substantially different between agonists and inverse agonists/
antagonist. In fact, two water molecules enter the cavity and
contribute to the stabilization of a novel interaction network
between the drug, Asp(3.32) and Asn(7.39) (Figure 4, panel B).
These two water molecules are present in the cavity for almost
100% of the simulation time and they exchange with the bulk with
a frequency of 120660 ns
21. Furthermore, while the N-C-C-O
dihedral angle remains in the g(2) conformation in all systems, the
value of the C-C-O-H dihedral angle varies substantially amongst
the different simulations (Table 1).
It has been recently proposed [30] that the protonation state of
Asp(2.50), a conserved aspartic acid in the transmembrane core of
the receptors, could be involved in receptor activation, suggesting
that when Asp(2.50) is deprotonated the equilibrium between the
active and the inactive state is shifted towards the active
configuration while when the residue is protonated the equilibrium
is shifted towards the inactive state. At the same time, mutagenesis
experiments in b1 and b2 adrenergic receptors have also shown
that mutations at position 2.50 not only affect receptor
downstream signaling, but can also alter agonist affinity leaving
antagonist affinity to the receptors unaltered [5,47,48,49].
In Table 1, the values of the C-C-O-H dihedral angle
(highlighted in Figure 1) of the bound ligand for both protonation
states of Asp(2.50) are reported. The dihedral angle is strongly
restrained in the g(2) conformation for the potent inverse agonist
carazolol bound to b2AR, while an equilibrium between the g(2)
and the g(+) conformation is present for cyanopindolol in b1AR.
Interestingly, these two equilibria are not substantially altered
upon changes of the protonation state of Asp(2.50), in agreement
with the mutagenesis experiments showing that antagonist-binding
is not substantially affected by mutations at position 2.50
[5,47,48,49] in b1 and b2 adrenergic receptors.
On the other hand, the equilibrium conformation of the C-O-
O-H dihedral angle is substantially altered upon changes in the
protonation state of Asp(2.50) in the case of isoprenaline-bound
b1AR and b2AR. When Asp(2.50) is protonated, the dihedral
angle is maintained in a conformation similar to the one found in
the simulations of inverse agonist bound receptors, while the
equilibrium drastically shifts towards the g(+) conformation for the
isoprenaline-bound b2AR and towards the trans conformation for
the isoprenaline-bound b1AR if Asp(2.50) is deprotonated. Since
the active state is indeed favored when Asp(2.50) is deprotonated
[30], the simulations suggest that the network of interactions
between isoprenaline and the helix III/helix VII interface in b
adrenergic receptors can differ significantly from the one suggested
by the crystal structure with inverse agonists.
In addition, simulations of unliganded b1AR and b2AR show
spontaneous stable binding of a sodium ion to Asp(3.32) inside the
binding pocket when Asp(2.50) is deprotonated. On the other hand,
such an event never takes place when Asp(2.50) is deprotonated.
Extracellular loops
The crystal structures of b adrenergic receptors have revealed that
the structure of the extracellular loops in these receptors able to bind
diffusible ligands is remarkably different from rhodopsin where the
N-terminus and ECL2 form a structured cap over the covalently
bound retinal to prevent ligand hydrolysis. In order to allow ligand
access to the binding pocket, ECL2 and ECL3 in adrenergic
receptors are mainly composed of polar and charged residues and,
unlike in rhodopsin, they do not prevent ligand access, even though
rearrangements of ECL2 are expected during ligand entry and exit
[50]. Recent NMR studies on rhodopsin [24] and on b2AR [25]
have revealed that the conformation of the extracellular surface
changesuponactivationandthat,inb2AR,drugsexhibitingdifferent
efficacies towards G-protein activation can stabilize distinct confor-
mations of the extracellular loops. All these findings demonstrate a
conformational coupling between this region and the orthosteric
binding site. In particular, it has been suggested that the extracellular
Lys305-Asp192 salt bridge in b2AR (Figure S3, Supplementary
Information) is weakened in the active state and that inverse agonists
may function in part by stabilizing bulky hydrophobic interactions
with Phe193 in ECL2 that block the motion of helix VI. These
findings areof special interestbecausealthough the ECL2 and ECL3
backbone conformations are very similar in b1 and b2 adrenergic
receptors, only 55% of their residues are identical, in contrast to the
94% sequence identity of the binding pockets.
Interestingly, while in the simulations of b2AR bound to
carazolol and isoprenaline the backbone structure of ECL2 and its
relative distance to TM7 remain approximately identical to the
crystal structure, in the simulation of unliganded b2AR ECL2
approaches the binding pocket (see Figure 5). Notably, even if the
salt bridge between Lys305 and Asp192 remains stable in all
simulations (Figure S3, Supplementary Information), the confor-
mation of Phe193 is substantially different in the three simulations
(see Figure 5): it remains close to the crystal structure conformation
Agonist Binding to b Adrenergic Receptors
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partially displaces towards helix III and VII in apo-b2AR and it
adopts g(+) and g(2) conformations interacting with the hydro-
phobic tail of the ligand in the isoprenaline-bound simulation
(Figure S4, Supplementary Information). As a consequence of the
displacement of Phe193 in the isoprenaline-bound case, the side
chain of Thr195 changes orientation and its hydroxyl group points
towards helix III eventually hydrogen bonding Phe193 backbone
oxygen.
In b1AR, on the other hand, the salt bridge between Lys305 and
Asp192 is absent, because lysine is replaced by the aspartic acid
Asp322. However, the high degree of structural similarity of the
backbone conformations of loops ECL2 and ECL3 in the two
receptors suggests that the role of these charged residues (lysine
and aspartic acid in b2AR and two aspartic acids in b1AR) is not
directly related to loop stabilization. At the same time, the
behavior of ECL2 is similar to the one observed in b2 receptor:
ECL2 remains close to the crystal structure conformation in the
Figure 4. Agonist interactions with helices III and VII. Panel A: Hydrogen-bond interaction network between Asp(3.32) and Asn(7.39) and
carazolol in b2AR (left) and cyanopindolol in b1AR (right). Panel B: MD snapshot of the hydrogen-bond interaction network between isoprenaline and
Asp(3.32), Asn(7.39) and internal water molecules in b2AR (left) and b1AR (right).
doi:10.1371/journal.pcbi.1001053.g004
Table 1. Ligand C-C-O-H dihedral angle populations.
System
Dihedral
conformation
Isoprenaline Asp(2.50)
deprotonated
Isoprenaline Asp(2.50)
protonated
Carazolol Asp(2.50)
deprotonated
Carazolol Asp(2.50)
protonated
b2AR g(2) 26% 85% 84% 95%
b2AR g(+) 70% 15% 16% 5%
b2AR trans 4% 0% 0% 0%
b1AR g(2) 42% 46% 46% 42%
b1AR g(+) 0% 47% 54% 58%
b1AR trans 58% 7% 0% 0%
Populations of the C-C-O-H dihedral angle of the ligand inside the binding pocket of b2AR and of b1AR along the MD simulations. The values of the dihedral angle are
calculated within 630u of the standard value (60u for g(2), 260u for g(+) and 180 for trans).
doi:10.1371/journal.pcbi.1001053.t001
Agonist Binding to b Adrenergic Receptors
PLoS Computational Biology | www.ploscompbiol.org 6 January 2011 | Volume 7 | Issue 1 | e1001053isoprenaline-bound simulation, while it approaches the binding
pocket in unliganded b1AR. At the same time, Phe201 in b1AR
(which is equivalent to Phe193 in b2AR) is also approaching helix
III in the isoprenaline-bound simulation but without changing side
chain rotameric conformation.
Remarkably, while in the simulations of b2AR the overall
structure of ECL3 remains very close to the crystal structure
independently of the nature of the bound ligand, the behaviour
of this loop is substantially different in the simulations of b1AR.
In fact, in the cyanopindolol-bound simulation of b1AR, ECL3 is
displaced from the binding site and Phe315 points towards the
extracellular side moving away from the ligand interaction
region. On the other hand, due to the additional interactions
that are formed between the catechol moiety of isoprenaline and
Asn(6.55), in the agonist-bound simulations ECL3 approaches
the binding site, with Phe315 playing a prominent role in the
hydrophobic stabilization of the binding site (see Figure 6). Since
ECL3 is linking helices VI and VII, this event could be a
precursor of an inward motion of the extracellular moiety of
helix VI towards helix III to favor the interaction between
Asn(6.55) and the b hydroxyl group of the agonist that is
supposed to be a later intermediate along the activation pathway
[8].
Discussion
Even though a clear understanding of the binding mode of
agonists to b adrenergic receptors would constitute a major step
for the development of selective drugs, no structural information
on agonist binding at atomic resolution is available yet and the
only resolved crystal structures have been obtained in complex
with inverse agonists or antagonists. As a consequence, the only
available information on possible agonist docking poses can be
inferred from rigid or semi-flexible docking protocols that use the
inactive receptor as a template and suffer from well-known
intrinsic limitations [12].
Even if the current capabilities of force-field based MD
simulations do not allow to reach all intermediates along the
activation pathway of adrenergic receptors, that are in the
milliseconds time scale [46], they are able to follow the early
local structural rearrangements that take place in the binding
pocket due to the effect of agonist binding. Moreover, despite the
limited statistic arising from the fact that only one replica per
system was run, they allow determining the newly formed pattern
of interactions between the bound ligand and the receptor taking
correctly into account protein flexibility, allosteric modulation and
internal solvation.
Figure 5. Conformations of second extracellular loop in b2AR. Conformation of the second extracellular loop (ECL2) and of Phe193 (sticks
representation) in MD simulations of unliganded b2AR (yellow), carazolol-bound b2AR (blue) and isoprenaline-bound b2AR (red). Isoprenaline and
carazolol are shown in transparency. Root mean square fluctuations are shown in Figure S5 of Supplementary Information.
doi:10.1371/journal.pcbi.1001053.g005
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formation of a complex hydrogen bond network between the
catechol moiety of isoprenaline and a set of residues in helices V
and VI, thus providing a possible explanation of the finding that
agonist binding is associated with a large change in enthalpy, while
antagonist binding is mainly entropy driven [43]. At the same
time, they rationalize the role of Ser(5.43) [6] and Ser(5.47) [6] in
agonist binding, while only Ser(5.42) [10] is involved in antagonist
binding. Interestingly, despite being in close proximity to the
bound ligand, Ser(5.43) does not interact directly with the drug,
but stabilizes another crucial residue, Asn(6.55), through the
formation of a stable hydrogen bond that restrains Asn(6.55)
conformation enabling a direct interaction between the NH2
moiety of the residue and one of the two hydroxyls of the catechol
group of isoprenaline. While it is acknowledged that Asn(6.55) is
involved in agonist binding through the formation of an hydrogen
bond with the b alcohol of the agonist in a late conformational
stage, the simulations suggest that Asn(6.55) can also play a major
role in agonist recognition in the early steps of the binding event.
In addition, the simulations do not support a large movement of
helix V during agonist binding that was suggested based on the
marked improvement in the calculated binding affinities for
agonist compounds using a semi-flexible docking approach [13].
In contrast, it turns out that only very limited helix V movement is
sufficient to achieve a very stable network of interactions that is a
direct consequence of the presence of internal water molecules that
help bridging the gap between the agonist and helix V.
In an analogous way, the presence of few internal water
molecules plays a major role in the stabilization of the interaction
between helices III and VII and the ethanolamine group of
isoprenaline. Despite the structural and chemical similarity
displayed by most agonists and antagonists, the binding mode of
isoprenaline to Asp(3.32) and Asn(7.39) is remarkably different
with respect to the antagonist binding mode suggested by the
crystal structures, due to the presence of the internal water
molecules. Interestingly, this decreased stability of the interaction
between Asn(7.39) and the ethanolamine group of agonists was
already reported by MD simulations of an endogenous agonist,
adrenaline, where the newly formed interactions appeared to be
dynamically less stable [51].
In addition, recent NMR studies on b2AR [25] have revealed a
direct coupling between the extracellular loops and the ability of
Figure 6. Conformations of third extracellular loop in b1AR. Conformation of the third extracellular loop (ECL3) and of Phe315 and Asn(6.55)
(sticks representation) in MD simulations of unliganded b1AR (yellow), cyanopindolol-bound b1AR (blue) and isoprenaline-bound b1AR (red).
Isoprenaline and cyanopindolol are shown in transparency.
doi:10.1371/journal.pcbi.1001053.g006
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different conformations of the extracellular loops can be stabilized
upon binding of ligands with different activities. In particular, it
has been suggested that the extracellular Lys305-Asp192 salt
bridge in b2AR is weakened in the active state and that inverse
agonists may function in part by stabilizing bulky hydrophobic
interactions with Phe193 in ECL2 that block the motion of helix
VI. Even though in our simulations we cannot observe any
substantial change in the Lys305-Asp192 salt bridge, probably due
to the fact that the time scales we are investigating are not
sufficient to allow for a complete relaxation of the receptor to the
active state, already in the submicrosecond time scale it is possible
to notice a different behavior of Phe193 depending on the type of
ligand that is bound to the receptor. The pronounced stability that
Phe193 displays in the antagonist bound simulations (due to the
presence of strong hydrophobic interactions) is lost in the
unliganded and in the isoprenaline-bound simulations, and the
conformational transitions of Phe193 side-chain allow for a closer
interaction between this residue and the Lys305-Asp192 salt
bridge, constituting a mean to potentially alter the strength of this
salt bridge.
In conclusion, the reported microsecond MD simulations of
agonist bound b adrenergic receptors propose a detailed and
dynamical description of agonist-receptor interactions, where
hydrogen bonding and internal water molecules play a crucial
role. In addition, the specific behavior of the extracellular loops in
the different systems can help rationalize the allosteric activity of
such loops and provide possible clues into drug-receptor
specificity.
Supporting Information
Dataset S1 Isoprenaline topology file.
Found at: doi:10.1371/journal.pcbi.1001053.s001 (0.01 MB
TXT)
Dataset S2 Cyanopindolol topology file.
Found at: doi:10.1371/journal.pcbi.1001053.s002 (0.02 MB
TXT)
Dataset S3 Carazolol topology file.
Found at: doi:10.1371/journal.pcbi.1001053.s003 (0.02 MB
TXT)
Figure S1 Time evolution of Asn(6.55) x2 angle in MD
simulations of isoprenaline-bound b1AR (red line) and b2AR
(green line).
Found at: doi:10.1371/journal.pcbi.1001053.s004 (1.81 MB TIF)
Figure S2 Helix III-helix V (red) and helix III-helix VI (blue)
distances in MD simulations of unliganded b1AR (left) and b2AR
(right). The helix III-helix V distance is defined as the Ca-Ca
distance between Asp(3.32) and Ser(5.43), while the helix III-helix
VI distance is defined as the Ca-Ca distance between Asp(3.32)
and Asn(6.55).
Found at: doi:10.1371/journal.pcbi.1001053.s005 (0.76 MB TIF)
Figure S3 Left panel: Lys305-Asp192 salt bridge in b2AR. Time
evolution of the Lys305-Asp192 salt bridge (Nf@Lys305-
Cc@Asp192 distance) in MD simulations of carazolol-bound
(blue), unliganded (yellow) and isoprenaline-bound (red) b2AR
and respective frequency distribution. (red) b2AR.
Found at: doi:10.1371/journal.pcbi.1001053.s006 (1.33 MB TIF)
Figure S4 Time evolution of the Phe193 x1 angle in MD
simulations of carazolol-bound (blue), unliganded (yellow) and
isoprenaline-bound (red) b2AR.
Found at: doi:10.1371/journal.pcbi.1001053.s007 (0.64 MB TIF)
Figure S5 Root mean square fluctuations of intracellular loop 2
in MD simulations of antagonist-bound (blue), unliganded (yellow)
and isoprenaline-bound (red) b2AR (left) and b1AR (right). Atom
index #1 corresponds to His172 in b2AR and to His180 in b1AR.
Found at: doi:10.1371/journal.pcbi.1001053.s008 (0.49 MB TIF)
Table S1 Hydrogen bond network between isoprenaline and
adrenergic receptors. The table shows the percentage of N-O or
O-O distances below 3.2 angstrom of the hydrogen bonds shown
in Figures 3 and 4 after equilibration.
Found at: doi:10.1371/journal.pcbi.1001053.s009 (0.04 MB
DOC)
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